Presented at EULAR 2025; OP0025. DOI: 10.1136/annrheumdis-2025-eular.B1313 Provided by European Alliance of Associations for Rheumatology, EULAR This story was originally published on Medical Xpress.

Updates in AxSpA from EULAR 2025 include 3-year data for bimekizumab, definition of difficult-to-manage subgroups, effectiveness of a digital therapeutic app, and a potential cell-therapy approach.

BARCELONA, Spain-- (BUSINESS WIRE)-- Hospital for Special Surgery (HSS) presented a research study at the European Alliance of Associations for Rheumatology (EULAR) Annual Meeting showing that an ...

Biogen Inc. (NASDAQ:BIIB) is one of the 11 most profitable NASDAQ stocks to buy now. On June 12, UCB and Biogen presented additional detailed results from the Phase 3 PHOENYCS GO study, evaluating ...

Zabotti, A., et al. (2023). EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis.

EULAR 2024 Preview: What's Not-to-Miss at This Year's Congress? Sara Freeman June 10, 2024 0 ...

The acceptable threshold for glucocorticoid use for lupus maintenance therapy should be 5 mg per day prednisone equivalent or less, according to the updated 2023 EULAR recommendations for the ...

UCB, a global biopharmaceutical company, today announced new three-year data from Phase 3 trials, and their open-label extensions, investigating BIMZELX® (bimekizumab-bkzx) in adults with active ...

The European Alliance of Associations for Rheumatology has announced the launch of the EULAR Impact of RMDs Survey, an online questionnaire targeted directly at RMD patients.

EULAR launches first European patient-filled survey about the impact of rheumatic and musculoskeletal diseases on individual’s lives First-of-its-kind online questionnaire allows collecting ...

Systemic juvenile idiopathic arthritis and adult-onset Still’s disease have been combined into one entity called Still’s disease in new recommendations document presented at the EULAR 2023 ...